Eli Lilly is a pharmaceutical company whose GLP-1 diabetes and obesity treatments have become blockbuster franchises.
For the fiscal year ended December 31, 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B, with operating cash flow of $16.8B. Source: Form 10-K filed February 12, 2026
Reported SEC XBRL figures. Each metric’s period and original filing are listed below.
Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.
It also develops therapies in oncology, immunology, and neuroscience.
Reported figures from Eli Lilly and Company's filings, pulled directly from SEC XBRL data rather than a third-party terminal. Each row links to the filing it came from.
| Metric | Value | Period | Source |
|---|---|---|---|
| Revenue | $65.2B | 2025-01-01 – 2025-12-31 | SEC filing |
| Net income | $20.6B | 2025-01-01 – 2025-12-31 | SEC filing |
| Operating cash flow | $16.8B | 2025-01-01 – 2025-12-31 | SEC filing |
| Diluted EPS | $22.95 | 2025-01-01 – 2025-12-31 | SEC filing |
| Net margin | 31.7% | 2025-01-01 – 2025-12-31 | SEC filing |
| Shares outstanding | 943M | As of 2026-02-09 | SEC filing |
Values are as tagged by the issuer in XBRL. Revenue for banks and insurers is net of interest expense where that is the reported line. Fiscal years that do not follow the calendar are shown by their period-end date. No price, market cap, or valuation multiple is shown because Yield Theory does not republish unlicensed market data.
Diluted EPS is the earnings figure behind the price-to-earnings ratio; the P/E multiple compression calculator shows how a change in that multiple moves a share price. Shares outstanding multiplied by the share price gives market capitalization.
For Eli Lilly and Company, the most important recurring operating and market variables are:
Each question starts with what the filings show, then why it matters. None of these is a rating or a forecast.
Mounjaro and Zepbound together accounted for 56% of 2025 revenue, with Mounjaro at $23.0 billion and Zepbound at $13.5 billion, and six products made up 82% of the $65.2 billion total. Item 1A flags this dependence on relatively few products and on three wholesalers; monitor U.S. realized prices, which fell even as volume surged.
The 10-K describes preliminary voluntary agreements with the U.S. government announced in November 2025 to lower Medicaid and certain other prices and to launch new medicines with more balanced pricing across developed nations, plus CVS Caremark's July 2025 removal of Zepbound as a preferred option. Model these against outside-U.S. revenue of $21.7 billion.
Item 1 lists capacity investments at new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany, and the Netherlands, and Item 1A notes that adding capacity takes years and regulatory approvals. Compare capital spending with the supply commentary and with R&D expense of $13.3 billion.
Gross margin reached 83.0% of revenue in 2025 and audited net income was $20.6 billion, or $22.95 per diluted share. Item 1 gives Mounjaro/Zepbound compound patent protection to 2036 in the U.S. but data protection only to 2027, and notes continued mass-compounded incretins; weigh these against orforglipron's regulatory review.
Operating cash flow was $16.8B, 0.81 times net income of $20.6B, for the fiscal year ended December 31, 2025.
Cash from operations trailed reported earnings. Working-capital build (receivables, inventory, prepayments) or non-cash gains are the usual reasons; check the cash-flow statement before relying on reported profit.
Net income was 31.7% of revenue for the fiscal year ended December 31, 2025, based on revenue and net income reported for the same period.
Net margin reflects the business model as much as execution, so compare it with companies in the same SEC industry and read the income statement for one-time items before treating it as a run rate.
Members-only research
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchHow we source and review company pages: research methodology.
| Politician | Trade date | Type | Owner | Amount | Source |
|---|---|---|---|---|---|
| Dan Newhouse | 2026-07-10 | Sale | Spouse | $1,001 - $15,000 | Filing #20034998 |
| Michael Rulli | 2026-07-01 | Sale | Self | $1,001 - $15,000 | Filing #20035147 |
| Gilbert Cisneros | 2026-06-10 | Purchase | Self | $50,001 - $100,000 | Filing #20034906 |
| Gilbert Cisneros | 2026-04-14 | Purchase | Self | $1,001 - $15,000 | Filing #20034500 |
| Lizzie Fletcher | 2026-04-08 | Sale | Self | $1,001 - $15,000 | Filing #20034413 |
| Byron Donalds | 2026-04-02 | Purchase | Spouse | $1,001 - $15,000 | Filing #20034478 |
| Byron Donalds | 2026-04-02 | Purchase | Self | $1,001 - $15,000 | Filing #20034478 |
| Alan Armstrong | 2026-03-27 | Sale | Self | $1,001 - $15,000 | Filing #fda235b3-bad7-4637-8fa1-053f354d929c |
| Gilbert Cisneros | 2026-03-13 | Sale | Self | $1,001 - $15,000 | Filing #20034285 |
| David Taylor | 2026-02-26 | Purchase | Self | $1,001 - $15,000 | Filing #20034138 |
All verified LLY congressional disclosures
Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.
Eli Lilly is a pharmaceutical company whose GLP-1 diabetes and obesity treatments have become blockbuster franchises.
For the fiscal year ended December 31, 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B, with operating cash flow of $16.8B. The figures come from Eli Lilly and Company's SEC XBRL filings.
The SEC lists Eli Lilly and Company's fiscal year end as December 31.
The current verified House and Senate snapshot contains 66 transaction rows for LLY, each linked to the original filing.
Eli Lilly and Company is headquartered in Indianapolis, Indiana and was founded in 1876.
This page does not rate LLY as a buy or sell. It sets out what Eli Lilly and Company reports, what investors should watch and the questions a thesis has to answer, with links to the SEC filings. It is research, not investment advice.
This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.
Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included